2-(4-cyanoanilino)-4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-6-(methoxymethyl)pyrimidine-5-carboxylic acid | 1037453-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(4-cyanoanilino)-4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-6-(methoxymethyl)pyrimidine-5-carboxylic acid
• CAS: 1037453-04-5
• 化学式: C₂₅H₂₂N₆O₃
• 分子量: 454.488
• InChiKey: IYTYKHJTWOEGDA-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  144
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-氨甲基吡啶 、 2-(4-cyanoanilino)-4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-6-(methoxymethyl)pyrimidine-5-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以48%的产率得到4-({4-[2-Cyanoethenyl]-2,6-dimethylphenyl}amino)-2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-N-(pyridin-2-ylmethyl)pyrimidine-5-carboxamide
  参考文献：
  名称：

  WO2008/80965

  摘要：

  公开号：
• 作为产物：
  描述：

  ethyl 2-(4-cyanoanilino)-4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-6-(methoxymethyl)pyrimidine-5-carboxylate 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到2-(4-cyanoanilino)-4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-6-(methoxymethyl)pyrimidine-5-carboxylic acid
  参考文献：
  名称：

  WO2008/80965

  摘要：

  公开号：

文献信息

• HIV inhibiting 5,6-substituted pyrimidines
  申请人：Janssen R&D Ireland

  公开号：EP2781510A1

  公开（公告）日：2014-09-24

  HIV replication inhibitors of formula having HIV (Human Immunodeficiency Virus) replication inhibiting properties, the preparation thereof and pharmaceutical compositions comprising these compounds. In particular the compounds have an improved ability to inhibit the replication of mutant strains, in particular of strains that have become resistant to one or more known NNRTI drugs, which strains are referred to as drug- or multidrug-resistant HIV strains

  艾滋病毒复制抑制剂配方 具有抑制 HIV（人类免疫缺陷病毒）复制的特性，其制备方法以及包含这些化合物的药物组合物。特别是，这些化合物对突变株，尤其是对一种或多种已知 NNRTI 药物产生耐药性的菌株（这些菌株被称为耐药或耐多药 HIV 菌株）的复制具有更好的抑制能力。
• HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES
  申请人：Janssen R&D Ireland

  公开号：EP2114902B1

  公开（公告）日：2014-09-17
• HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES
  申请人：Guillemont Jerôme Emile Georges

  公开号：US20100261722A1

  公开（公告）日：2010-10-14

  HIV replication inhibitors of formula R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 , R 3 , R 7 and R 8 are hydrogen; hydroxy; halo; C 3-7 cycloalkyl; C 1-6 alkyloxy; carboxyl; C 1-6 alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C 1-6 alkyl)amino; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; —C(═O)R 10 ; C 1-6 alkyl optionally substituted with halo, cyano or —C(═O)R 10 ; optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl; R 4 and R 9 are hydroxy; halo; C 3-7 cycloalkyl; C 1-6 alkyloxy; carboxyl; C 1-6 alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C 1-6 alkyl)amino; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; —C(═O)R 10 ; cyano; —S(═O) r R 10 ; —NH—S(═O) 2 R 10 ; —NHC(═O)H; —C(═O)NHNH 2 ; —NHC(═O)R 10 ; Het; —Y-Het; optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; R 5 is C 2-6 alkenyl or C 2-6 alkynyl both substituted with cyano, aminocarbonyl, mono- and di(C 1-6 alkyl)aminocarbonyl, aryl, pyridyl, thienyl, furanyl, or with one or two C 1-6 alkyloxy groups; Het; —C(═O)NR 5a R 5b ; —CH(OR 5c )R 5d ; X is —NR 1 —, —O—, —CH 2 —, or —S—; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
• US8318736B2
  申请人：——

  公开号：US8318736B2

  公开（公告）日：2012-11-27
• [EN] HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES<br/>[FR] PYMIRIDINES SUBSTITUÉES EN 5,6, INHIBITRICES DU VIH
  申请人：TIBOTEC PHARM LTD

  公开号：WO2008080965A2

  公开（公告）日：2008-07-10

  [EN] R¹ is hydrogen; aryl; formyl; C_{1_6}alkylcarbonyl; C_{1_}6alkyl; C_{1_6}alkyloxycarbonyl; R², R³, R⁷ and R⁸ are hydrogen; hydroxy; halo; C_3-7cycloalkyl; C_{1_6}alkyloxy; carboxyl; C_{1_6}alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C_{1_6}alkyl)amino; polyhaloC_1-6alkyl; polyhaloC_1-6alkyloxy; -C(=O)R¹⁰; C_{1_6}alkyl optionally substituted with halo, cyano or -C(=O)R¹⁰; optionally substituted C_{1_6}alkyl, C_2-6alkenyl, or C2-6alkynyl; R⁴ and R⁹ are hydroxy; halo; C_{3_7}Cycloalkyl; C_{1_6}alkyloxy; carboxyl; C_{1_6}alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C_{1_6}alkyl)amino; polyhaloC_{1_6}alkyl; polyhaloC_{1_6}alkyloxy; -C(=O)R¹⁰; cyano; -S(=O)_rR¹⁰; -NH-S(=O)₂R¹⁰; -NHC(=O)H; -C(=O)NHNH₂; -NHC(=O)R¹⁰; Het; -Y-Het; optionally substituted C_{1_6}alkyl, C_2-6alkenyl or C_2-6alkynyl; R⁵ is C_2-6alkenyl or C_2-6alkynyl both substituted with cyano, aminocarbonyl, mono- and di(C_{1_6}alkyl)aminocarbonyl, aryl, pyridyl, thienyl, furanyl, or with one or two C_{1_6}alkyloxy groups; Het; -C(=O)NR^5aR^5b; -CH(OR^5c)R^5d; X is -NR¹-, -O-, -CH₂-, or -S-; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
  [FR] L'invention porte sur la formule d'un inhibiteur de la réplication du VIH dans laquelle:R1 est hydrogène; aryle; foumyle; C1_6alkylcarbonyle; C1_6alkyle; C1_6alkyloxycarbonyle; R2, R3, R7 et R8 sont hydrogène; hydroxy; halo; C3-7cycloalkyle; C1_6alkyloxy; carboxyle; C1_6alkyloxycarbonyle; cyano; nitro; amino; mono- ou di(C1_6alkyl)amino; polyhaloC1-6alkyle; polyhaloC1-6alkyloxy; -C(=O)R10; C1_6alkyle facultativement substitué par halo, cyano ou -C(=O)R10; facultativement substitué par C1_6alkyle, C2-6alcényle, ou C2-6alkynyle; R4 et R9 sont hydroxy; halo; C3_7Cycloalkyle; C1_6alkyloxy; carboxyle; C1_6alkyloxycarbonyle; formyle; cyano; nitro; amino; mono- ou di(C1_6alkyl)amino; polyhaloC1_6alkyle; polyhaloC1_6alkyloxy; -C(=O)R10; cyano; -S(=O)rR10; -NH-S(=O)2R10; -NHC(=O)H; -C(=O)NHNH2; -NHC(=O)R10; Het; -Y-Het; facultativement substitué C1_6alkyle, C2-6alcényle ou C2-6alkynyle; R5 est C2-6alcényle ou C2-6alkynyle tous deux substitués par cyano, aminocarbonyle, mono- et di(C1_6alkyl)aminocarbonyle, aryle, pyridyle, thiényle, furanyle, ou par un ou deux groupes C1_6alkylyoxy; Het; -C(=O)NR5aR5b; -CH(OU5c)R5d; X is -NR1-, -O-, -CH2-, ou -S-; L'invention porte aussi sur des préparations pharmaceutiques contenant ces composés dont ils sont le principe actif, et sur les procédés de préparation desdits composés et desdites compositions.